Moderately to Severely Active Crohn's Disease in Higher-Risk Patients When Corticosteroids and Immunomodulators Have Not Achieved Durable Remission
This protocol describes the next clinical step for higher-risk patients with moderately to severely active Crohn's disease who did not reach durable, steroid-free remission on an initial corticosteroid-based regimen supported by a maintenance immunomodulator.
Patient Population
Patients with moderately to severely active Crohn's disease who carry risk features for disease progression — including young age at diagnosis, ileal or ileocolonic disease location, extensive disease, large or deep ulcers on endoscopy, fever, significant weight loss, or abdominal pain and tenderness.
Why Escalation Applies — Previous Treatment Did Not Reach Its Targets
The preceding treatment line used oral corticosteroids for short-term induction of remission, followed by a steroid-sparing maintenance immunomodulator (azathioprine, 6-mercaptopurine, or methotrexate). Escalation is indicated when that approach fails to deliver clinical improvement within the expected 2–4 week window (with maximal benefit by 12–16 weeks) and does not sustain durable steroid-free clinical and endoscopic remission.
Next-Step Approach (Partial Overview)
This protocol advances to advanced biologic-based therapy for both induction and maintenance of remission. For biologic-naive patients at higher risk, combination therapy is a key preferred strategy — but the specific agents, alternatives, and the full treatment algorithm are available in the structured protocol below.
Treatment Targets
The goal is clinical and biomarker response within 12 weeks of initiating treatment, followed by durable steroid-free remission — defined as a CDAI score below 150 and absence of mucosal ulceration on endoscopy.
References
DOI: 10.14309/ajg.0000000000003465
- We recommend oral corticosteroids for short-term induction of remission in patients with moderately to severely active CD (strong recommendation, low level of evidence).
- Individuals are considered to have moderate–severe disease if they have not responded to treatment for mild–moderate disease or if they present with more prominent symptoms such as fever, significant weight loss, abdominal pain or tenderness, intermittent nausea or vomiting.
- We recommend anti-tumor necrosis factor (TNF) agents (intravenous infliximab, subcutaneous adalimumab, subcutaneous certolizumab pegol) for induction and maintenance of remission for moderately to severely active CD (strong recommendation, moderate level of evidence).
- We recommend combination therapy of intravenous infliximab with immunomodulators (thiopurines) as compared with treatment with either immunomodulators alone or intravenous infliximab alone in patients with CD who are naive to those agents (strong recommendation, moderate level of evidence).
- Regimens are generally chosen according to the patient's risk profile and disease severity with a goal to achieve clinical and biomarker response within 12 weeks of treatment initiation followed by durable steroid-free control of disease activity including both clinical and endoscopic remission.
View source ↗